Background {#S0001}
==========

Gemcitabine (GEM) is one of the anticancer drugs that is often used for patients with advanced cancer[@CIT0001] GEM-containing regimens are used for patients with pancreatic cancer, biliary tract cancer, lung cancer, sarcoma, urothelial cancer, or breast cancer.[@CIT0002]--[@CIT0007] Literature is limited on the responses of GEM-containing regimens in patients with advanced cancers[@CIT0005],[@CIT0008]--[@CIT0010]; this necessitates the improvement of treatment efficacies of GEM-containing regimens in patients with advanced cancers.

A previous study reported that GEM (2ʹ,2ʹ-difluorodeoxycytidine) is metabolized into an inactive metabolite 2,2ʹ-difluorodeoxyuridine by various microbes that express a long isoform of the bacterial enzyme cytidine deaminase (CDD~L~)[@CIT0011] In other previous reports, the treatment of tumor-bearing mice with antibiotics eradicates the bacteria from the tumor tissue and consequently increases the concentration of GEM in the tumor tissue[@CIT0012] Increased concentration of GEM in the tumor tissue resulted in robust tumor regression, whereas the mouse not treated with GEM did not exhibit tumor regression[@CIT0012] Moreover, various bacteria expressed CDD~L~ in human pancreatic cancer tissue, and these bacteria potently conferred the resistance of GEM in the cancer cell line in vitro[@CIT0012] Therefore, the bacteria that express CDD~L~ in tumor tissue may be related to the low treatment efficacies of GEM in human and that the addition of antibiotics to a regimen-containing GEM would augment its efficacy. However, no previous report had examined whether the addition of antibiotics augments the treatment efficacy of GEM in patients with advanced cancer.

In this study, we tried to assess whether antibiotics given for treatment or prevention of infection augment the treatment efficacy of GEM-containing regimens in patients with various types of advanced cancers.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

Medical records of patients who were diagnosed with cancer histopathologically and were treated with GEM-containing regimens (n=169) were retrospectively reviewed at the Department of Medical Oncology, Tohoku University Hospital from 2006 to 2018. Patients with advanced stage of pancreatic cancer, biliary tract cancer, duodenal cancer, cancer of unknown primary, neuroendocrine carcinoma, sarcoma, and urinary bladder cancer were included in this study. Patients with stage III or stage IV cancers were included in the antibiotics-untreated and antibiotics-treated group. Proportions of patients with stage III or IV cancer were similar between the two groups.

Inclusion criteria of this study included: 1) patients who had been histologically confirmed carcinoma or sarcoma; 2) patients who had unresectable cancer (or sarcoma) or metastatic lesion; 3) patients who had been treated with at least one course of GEM-containing regimen; 4) patients who had at least one measurable cancer (or sarcoma) lesion; 5) patient in whom the treatment efficacies of GEM-containing regimen in cancer (or sarcoma) had been assessed by computed tomography (CT) at least once. In all, there were 196 patients who met the inclusion criteria. Patients who did not meet inclusion criteria were all excluded from the analyses in this study.

Treatment methods {#S0002-S2002}
-----------------

The doses and schedules of GEM treatment in this study were as follows. GEM alone (plus erlotinib): GEM 1000 mg/m^2^, days 1, 8 and 15 (erlotinib 100 mg/body, days 1--28) every 4 weeks; GEM plus nanoparticle albumin binding paclitaxel (nabPTX): GEM 1000 mg/m^2^, nabPTX 125 mg/m^2^, days 1, 8, 15, every 4 weeks; GEM plus cisplatin (plus S-1): GEM 1000 mg/m^2^, cisplatin 25 mg/m^2^, days 1, 8 (S-1 80 mg/m^2^, days 1--14, every 3 weeks; GEM plus docetaxel: GEM 900 mg/m^2^, day 1, 8, docetaxel 70 mg/m^2^ day 8, every 3 weeks.

Antibiotics were administered according to the drug attachment (e.g., levofloxacin hydrate: oral administration, 500 mg/body/day; cefdinir: oral administration, 300 mg/body/day; meropenem hydrate: intravenous administration, 0.5--1 g/body/day.) The administration period of antibiotics was determined by the chief physician of each patient.

Evaluation {#S0002-S2003}
----------

Patients were assigned into two groups. The first was the antibiotics-treated group where patients had been treated with antibiotics from the start of the GEM-containing regimen to the first imaging evaluation of the efficacy of GEM-containing regimen using CT (antibiotics-treated group). The other group was the antibiotics-untreated group where patients had not been treated with antibiotics from the start of the GEM-containing regimen to the first CT evaluation of the efficacy of the GEM-containing regimen.

Responses were assessed using Response Criteria in Solid Tumor version 1.0[@CIT0013] The rates of complete response (CR; all signs of cancer disappeared by treatment with GEM-containing regimen) and partial response (PR; defined as a ≥30% reduction in the diameter of measurable lesions on CT) were combined and defined as the response rate. CR, PR, and stable disease (defined as a \<30% reduction and a \<20% increase in the diameter of measurable lesions as shown on CT) rates were combined, and these rates were defined as the disease control rate. In this study, the relative dose intensity of GEM was defined as the ratio of the total actual dose of GEM delivered to patients to the planned dose of GEM. All toxicities were reviewed from medical records and were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0[@CIT0014]

Statistical analysis {#S0002-S2004}
--------------------

The median progression-free survival (PFS) time and median overall survival (OS) time were calculated using the Kaplan--Meier method. *P*-values of the response rate and disease control rate were based on Fisher's exact test. All statistical analyses including univariate analysis, multivariate analysis, Pearson's chi-squared test, and Wilcoxon Mann--Whitney test were performed using JMP^®^ 11 (SAS Institute Inc., Cary, NC, USA). All differences were regarded as statistically significant when *P*\<0.05.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

We identified 169 patients who were treated with GEM-containing regimen (antibiotics-untreated group=93; antibiotics-treated group=76). Patient characteristics are presented in [Table 1](#T0003){ref-type="table"}. Approximately, 80% of the subjects had pancreatic or biliary tract cancer. Relative dose intensities of GEM in the antibiotics-untreated and antibiotics-treated groups were 81.1% and 78.9%, respectively. Proportions of sex, previous surgery, types of GEM-containing regimens were similar between the two groups.Table 1Patient characteristicsAntibiotics-untreated groupAntibiotics-treated group*P*-valueNumber9376Sex (%)0.785 Male56 (60.2)46 (60.5) Female37 (39.8)30 (39.5)Mean age (range)63.9 (29--80)63.0 (31--84)Cancer type (%)0.346 Pancreatic cancer60 (64.5)45 (59.2) Biliary tract cancer16 (17.2)18 (23.7) Sarcoma9 (9.7)9 (11.8) CUP3 (3.2)2 (2.6) Duodenal cancer3 (3.2)1 (1.3) Neuroendocrine carcinoma1 (1.1)0 (0.0) Breast cancer1 (1.1)0 (0.0) Ulinary bladder cancer0 (0.0)1 (1.3)Tumor stage0.891 III8 (8.6)7 (9.2) IV85 (91.4)69 (90.8)Operation history (%)0.755 +23 (24.7)23 (30.3) −70 (75.3)53 (69.7)GEM including regimen (%)0.412 GEM alone48 (52.1)34 (44.7) GEM plus nabPTX20 (22.9)20 (26.3) GEM plus cisplatin12 (12.5)12 (15.8) GEM plus docetaxel9 (9.4)9 (11.8) GEM plus cisplatin plus S-13 (2.1)0 (0.0) GEM plus elrotinib1 (1.0)1 (1.3)Relative dose intensity of GEM (%)81.178.90.788Treated antibiotics New quinolone38 (50.0) Second-generation cephem3 (3.9) Third-generation cephem15 (19.7) Fourth-generation cephem13 (17.1) Carbapenem3 (3.9) β-Lactamase inhibitor2 (2.6) Penicillin1 (1.3)Reason of antibiotics treatment Because of infection16 (21.1) To prevent infection60 (78.9)[^1][^2]

Efficacies of GEM-containing regimens {#S0003-S2002}
-------------------------------------

We calculated the response rate of patients to GEM-containing regimens. As shown in [Table 2](#T0004){ref-type="table"}, the response rates in the antibiotics-untreated and antibiotics-treated groups by GEM-containing regimens were 15.1% and 27.6%, respectively. Disease control rates in the antibiotics-untreated and antibiotics-treated groups by GEM-containing regimens were 51.6% and 72.4%, respectively. The response and disease control rates were significantly higher in the antibiotics-treated group than in the antibiotics-untreated group.Table 2Response rate of gemcitabine-containing regimensCRPRSDPDRR (%)Antibiotics-untreated group014344515.1Antibiotics-treated group021342127.6[^3][^4]

As shown in [Figure 1](#F0001){ref-type="fig"}, the median PFS times of the antibiotics-untreated and antibiotics-treated groups were 2.5 (95% CI: 1.86--3.73) days and 4.93 (95% CI: 3.47--6.0) months, respectively. The median PFS rate was significantly higher in the antibiotics-treated group than in the antibiotics-untreated group (*P*\<0.0001, log-rank test). As shown in [Figure 2](#F0002){ref-type="fig"}, the median OS times of the antibiotics-untreated and antibiotics-treated groups were 7.53 (95% CI: 5.63--9.57) months and 13.83 (95% CI: 10.83--16.43) months, respectively. The median OS rate was significantly higher in the antibiotics-treated group than in the antibiotics-untreated group (*P*\<0.0001, log-rank test). The median PFS and the median OS of the patients with each cancer type in antibiotics-treated group and antibiotics-untreated group were shown in [Table S1](#ST0001). In all cancer types, both the median PFS and the median OS of antibiotics-treated group were longer than these of antibiotics-untreated group. Especially, in pancreatic cancer, both the median PFS and the median OS of the antibiotics-treated group were significantly longer than those of the antibiotics-untreated group. In sarcoma, the median OS of the antibiotics-treated group was significantly longer than that of antibiotics-untreated group. Original data of each patient were shown in [Table S2](#ST0002).Figure 1Kaplan--Meier curve of the PFS rate in the antibiotics-untreated group and antibiotics-treated group.**Abbreviation:** PFS, progression-free survival.Figure 2Kaplan--Meier curve of the OS rate with the antibiotics-untreated group and antibiotics-treated group.**Abbreviation:** OS, overall survival

Toxicities {#S0003-S2003}
----------

Toxicities by GEM-containing regimens in the antibiotics-untreated and antibiotics-treated group are shown in [Table 3](#T0005){ref-type="table"}. The proportions of patients with severe leukopenia and neutropenia by GEM-containing regimens in the antibiotics-treated group were higher than those in the antibiotics-untreated group. Patients with a febrile neutropenia were included only in the antibiotics-treated group. The incidence rates of anemia, thrombocytopenia, and elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level were similar between the two groups. No patients died from adverse events of GEM-containing regimens.Table 3Severe (grade 3 or 4) toxicities by gemcitabine-containing regimensAntibiotics-untreated group (n=93)Antibiotics-treated group (n=76)Leukopenia14 (15.1)36 (47.4)Neutropenia27 (29.0)42 (55.3)Anemia15 (16.1)12 (15.8)Thrombocytopenia10 (10.7)7 (9.2)Febrile neutropenia0 (0.0)2 (2.6)Elevated AST/ALT7 (7.5)6 (7.9)[^5]

Univariate and multivariate analyses {#S0003-S2004}
------------------------------------

We performed univariate and multivariate analyses for the relationship between the responses to GEM-containing regimens and patient background or a severe neutropenia by GEM-containing regimens. Results of univariate and multivariate analyses are shown in [Table 4](#T0006){ref-type="table"}. We found statistically significant correlations between the response by GEM-containing regimens and antibiotic treatment (univariate analysis: *P*=0.0305, multivariate analysis: *P*=0.0314). Seven factors (age, sex, severe neutropenia, operation history, tumor stage, cancer primary site, and type of GEM-containing regimens) analyzed did not significantly correlate with the response of GEM-containing regimens.Table 4Univariate and multivariate analyses for the relationship between the response to the gemcitabine-containing regimens and patients' background or toxicity by gemcitabine-containing regimensn (%)Univariete analysisMultivariate analysis*P*-valueOR (95% CI)*P*-valueSex Male102 (60.3)0.56211.39 (0.632--3.058)0.4129 Female67 (39.7)Age ≧6590 (53.3)0.41441.733 (0.765--3.926)0.1877\<6579 (46.7)AntibioticsUntreated93 (55.0)0.03052.444 (1.083--5.519)0.0314Treated76 (45.0)Severe (grade 3 or 4) neutropeniaNegative110 (65.1)0.69750.696 (0.293--1.651)0.4103Positive59 (34.9)Operaion historyNegative123 (72.8)0.11480.364 (0.129--1.033)0.0577Positive46 (27.2)Tumor stageIII15 (8.9)0.43602.321 (0.473--11.392)0.2995IV154 (91.1)Cancer typePancreatic cancer105 (62.1)0.77990.919 (0.383--2.205)0.8500Other cancers64 (37.9)Type of GEM-containing regimenGEM alone82 (48.5)0.07001.997 (0.842--4.738)0.1165Combination of GEM and other anticancer drug87 (51.5)[^6][^7]

Discussion {#S0004}
==========

A previous study[@CIT0012] revealed that the antitumor efficacy of GEM was augmented by the addition of antibiotics in tumor-bearing mice compared to the antitumor efficacy of GEM alone. However, no previous report has demonstrated the augmentation of antitumor efficacy of GEM by addition of antibiotics in cancer patients. In this study, we observed that the treatment efficacy of GEM-containing regimens with antibiotics was augmented compared to that of GEM-containing regimens without antibiotics in patients with various types of advanced cancer. In all cancer type in this study, there had been tendency that both the median PFS and the median OS in the antibiotics-treated group were longer than these of antibiotics-untreated group.

A previous study[@CIT0012] demonstrated that antibiotics therapy (150 mg/kg of new quinolone) even for 2 days significantly removed bacteria from the tumor tissue in mice and consequently reduced the CDD~L~ from bacteria. The reduction of CDD~L~ resulted in the low metabolism of GEM by bacteria and the high concentration of GEM in the tumor tissue[@CIT0012] The dosage of antibiotics in that study[@CIT0012] was similar to those usually used in patients in clinical practice. In the present study, all antibiotics were given in doses similar to those in clinical practice. In this study, as we did not investigate the amount of bacteria in the cancer tissue from patients, it is unclear whether bacteria were sufficiently removed from the tumor tissue by the antibiotics therapy. However, based on a previous study,[@CIT0012] the dosage of antibiotics used in the present study appeared to be sufficient to reduce the bacteria from the tumor tissue. Moreover, in the present study, the augmentation of the treatment efficacy of GEM-containing regimen by the addition of antibiotics might be attributable to the removal of bacteria from the cancer tissue, which consequently increased the concentration of GEM in cancer tissues.

In this study, the incidence rates of severe leukopenia and neutropenia by GEM-containing regimens were higher in the antibiotics-treated group than in the antibiotics-untreated group. Usually, patients who have grade 3 or 4 of leucopenia or neutropenia during chemotherapy are treated with antibiotics to prevent infections[@CIT0015] Therefore, it is inevitable that the antibiotics-treated group includes patients with severe leukopenia or neutropenia. The proportions of anemia, thrombocytopenia, or elevated AST or ALT level were similar between two groups, suggesting that the addition of antibiotics do not increase the adverse effects by GEM-containing regimens.

Alteration of gut microbiota by antibiotics influenced the efficacies and toxicities of irinotecan as irinotecan metabolism was affected by bacteria in mice gut[@CIT0016] Antibiotic treatment might change the gut microbiota in patients in the present study and might influence the metabolism of GEM by the bacteria in the gut similar to that in a previous report[@CIT0016] These changes might elevate the blood concentration of GEM, resulting in higher toxicities with GEM-containing regimen in the antibiotics-treated group. However, the incidence rates of anemia, thrombocytopenia, and elevated AST or ALT level were similar between the two groups in the present study. Therefore, it is assumed that the general concentration of GEM is not elevated but elevated locally in the tumor tissue.

The univariate and multivariate analyses in the present study revealed that antibiotic treatment significantly correlated to the response of GEM-containing regimens. These results suggest that the addition of antibiotics was the cause of improvement of the treatment of efficacies of GEM-containing regimens.

This study has some limitations. First, this study has a retrospective design. Second, the number of patients is relatively small. Third, several previous studies have reported the influence of antibiotics on the activity of cytochrome P450 (CYP) or on the induction of CYP in humans.[@CIT0017]--[@CIT0020] The change in CYP activity or in CYP induction by antibiotics influences the metabolisms of other anticancer drugs.[@CIT0021]--[@CIT0024] The metabolism of GEM is possibly modified by CYP mediated by antibiotics. However, no study has reported about GEM metabolism by CYP. Therefore, it is still uncertain whether the blood concentration of GEM changes via CYP. Fourth, the timing and duration of antibiotic treatment during GEM-containing regimens varied with each patient. However, the background of the two groups was very similar, except that antibiotics were added to GEM-containing regimens only in the antibiotics-treated group. Thus, the improvement of treatment efficacy of GEM-containing regimens might be attributable to the addition of antibiotics to patients in the antibiotics-treated group. Forth, although there are several mechanisms modulating the sensitivities of GEM in cancer patients, we did not investigate the GEM resistant mechanisms in patients in this study. It has been reported that the dysregulation of proteins participating in GEM metabolism pathway or the high expression of GEM efflux pump is the mechanisms responsible for GEM resistance.[@CIT0025]--[@CIT0027] Moreover, it was also reported that *BRCA1 associated protein 1 gene (BAP1)* mutation is responsible for the sensitivity of GEM in patients with malignant mesothelioma.[@CIT0028] To investigate whether these resistant mechanisms influence on efficacies of the antibiotics and GEM-containing regimen combination therapy or not is needed.

Conclusion {#S0005}
==========

The addition of antibiotics to GEM-containing regimens might be a potential therapeutic option to improve treatment efficacies of GEM-containing regimens in patients with advanced cancer.

Supplementary materials {#S0010}
=======================

Table S1The median progression free survival time (PFS) or the median OS of the patients with biliary tract cancer, pancreatic cancer, sarcoma and other cancers in antibiotics-untreated group and antibiotics-treated groupPrimary siteMedian PFS (months)*P*-valueMedian OS (months)*P*-valueAntibiotics-untreated gourpAntibiotics-treated groupAntibiotics-untreated gourpAntibiotics-treated groupBiliary tract3.45.40.158010.614.30.4305Pancreas2.54.20.00356.613.80.0020Sarcoma1.95.10.26424.010.90.0400Other cancers4.07.90.14459.910.80.5997[^8] Table S2Patient's original data in the present studyAgeSexPrimary siteOperation historyGEM-containing regimenGEM containing regimenDate of deathAntibiotics treatmentDate of startDate of discontinuation69FemalePancreasNoGC11-05-201731-08-201831-08-2018Carbapenem63FemaleBiliary tractNoGC14-11-200801-05-200929-07-2009Carbapenem67FemalePancreasNoGEM27-06-200824-09-200814-11-2008Carbapenem54MaleBiliary tractNoGC05-07-201712-10-201731-08-2018Cephem67MaleBiliary tractNoGC15-10-201517-12-201508-04-2017Cephem62MaleBiliary tractNoGC17-10-201302-07-201520-08-2015Cephem69MalePancreasNoGC25-07-201626-09-201623-05-2017Cephem75FemalePancreasNoGC16-06-201529-04-201624-08-2016Cephem25MaleSarcomaNoGD16-12-201325-05-201725-11-2017Cephem32FemaleSarcomaNoGD30-10-201716-11-201712-01-2018Cephem68MaleBiliary tractNoGEM24-11-201520-06-201731-08-2018Cephem57MaleCUPNoGEM18-08-201710-11-201702-01-2018Cephem74FemalePancreasNoGEM05-04-201002-06-201004-06-2010Cephem76FemalePancreasNoGEM11-12-200610-10-200811-12-2008Cephem70FemalePancreasNoGEM24-08-200604-12-200812-01-2009Cephem49MalePancreasNoGEM24-07-201405-12-201421-02-2015Cephem67MalePancreasNoGEM06-02-201827-02-201829-04-2018Cephem66MalePancreasNoGEM23-03-201724-05-201726-06-2018Cephem66FemalePancreasNoGEM11-12-201731-08-201831-08-2018Cephem68FemalePancreasNoGEM12-05-201719-07-201724-09-2017Cephem50MalePancreasNoGEM30-09-201609-12-201623-04-2017Cephem72MalePancreasNoGEM04-08-201615-09-201617-11-2016Cephem84FemaleBiliary tractNoGnP27-12-201731-08-201831-08-2018Cephem42FemaleBiliary tractNoGnP16-03-201612-09-201601-02-2017Cephem62FemaleBiliary tractNoGC31-05-201601-11-201601-11-2016New quinolone58MaleCUPNoGC26-03-201018-11-201014-02-2011New quinolone70MalePancreasNoGC31-10-201512-01-201625-03-2016New quinolone66MalePancreasNoGC22-08-201429-01-201519-03-2015New quinolone68FemaleUlinary bladderNoGC12-09-201105-12-201116-04-2012New quinolone36MaleSarcomaNoGD19-06-201507-04-201607-04-2016Ne w quinolone59MaleBiliary tractNoGEM30-08-201611-04-201731-07-2017New quinolone61MaleBiliary tractNoGEM04-06-201223-08-201225-10-2012New quinolone58MaleBiliary tractNoGEM01-11-201231-01-201303-01-2014New quinolone80FemaleBiliary tractNoGEM28-02-201116-05-201121-10-2011New quinolone59FemaleBiliary tractNoGEM31-07-200912-11-200901-04-2011New quinolone78MaleBiliary tractNoGEM18-09-200706-11-200910-05-2010New quinolone54MalePancreasNoGEM26-03-201528-05-201516-07-2015New quinolone72MalePancreasNoGEM13-02-201531-08-201831-08-2018New quinolone64MalePancreasNoGEM21-02-201108-08-201129-03-2012New quinolone66MalePancreasNoGEM24-09-201011-03-201128-05-2011New quinolone74MalePancreasNoGEM26-05-201005-01-201103-08-2011New quinolone48MalePancreasNoGEM06-04-200921-08-200908-05-2010New quinolone71MalePancreasNoGEM06-09-200716-11-200718-01-2008New quinolone70MalePancreasNoGEM26-05-200623-05-200705-02-2010New quinolone69FemalePancreasNoGEM05-10-200621-02-200723-11-2007New quinolone73MaleBiliary tractNoGnP18-05-201516-07-201511-09-2015New quinolone77MalePancreasNoGnP02-07-201526-10-201518-06-2016New quinolone58MalePancreasNoGnP12-12-201120-01-201210-02-2012New quinolone87FemalePancreasNoGnP16-02-201823-04-201819-06-2018New quinolone70MalePancreasNoGnP04-09-201724-05-201805-07-2018New quinolone80MalePancreasNoGnP30-08-201718-12-201719-02-2018New quinolone63MalePancreasNoGEM28-06-201721-08-201731-08-2018Penicilline66MalePancreasNoGEM25-11-201401-09-201501-04-2016β-lactamase inhibitor61FemaleBiliary tractNoGC25-08-201418-09-201425-09-2014None70MaleBiliary tractNoGC24-03-201430-05-201429-07-2014None78FemaleBiliary tractNoGC16-02-201613-06-201631-07-2016None71MaleBiliary tractNoGC12-08-201607-10-201605-05-2017None68FemaleBiliary tractNoGC14-07-201407-10-201415-05-2015None75FemaleBiliary tractNoGC29-01-201312-09-201317-08-2014None58MaleBiliary tractNoGC21-01-201321-09-201306-12-2013None69FemaleBiliary tractNoGC10-05-201029-06-201021-02-2011None79FemaleCUPNoGC31-05-201224-05-201330-09-2013None50MaleNECNoGC06-10-201420-04-201527-09-2015None64FemaleBiliary tractNoGCS09-10-201516-06-201606-04-2017None74MaleBiliary tractNoGCS06-01-201615-07-201612-10-2016None32MaleSarcomaNoGD06-03-201721-03-201704-04-2017None52FemaleSarcomaNoGD31-10-201626-12-201628-02-2017None70MaleBiliary tractNoGEM10-02-201112-04-201128-06-2011None72FemaleBiliary tractNoGEM04-09-200828-10-200817-04-2009None78MaleCUPNoGEM27-06-201725-07-201705-10-2017None70MaleCUPNoGEM14-04-200818-08-200828-08-2008None46FemaleBreastNoGEM10-04-200822-05-200818-02-2009None76MalePancreasNoGEM20-09-201605-01-201713-05-2017None29MalePancreasNoGEM06-01-201428-02-201420-06-2014None80FemalePancreasNoGEM04-09-201430-10-201414-02-2015None42MalePancreasNoGEM22-08-201315-12-201315-12-2013None61FemalePancreasNoGEM17-01-201417-09-201414-11-2014None65MalePancreasNoGEM16-05-201308-10-201302-10-2013None45FemalePancreasNoGEM23-04-201306-06-201312-07-2013None61MalePancreasNoGEM05-10-201206-11-201221-11-2012None55femalePancreasnoGEM19-04-201318-06-201323-09-2013none69malePancreasnoGEM15-01-201325-06-201305-07-2014none63femalePancreasnoGEM26-04-201201-06-201201-09-2012none56malePancreasnoGEM22-09-201131-10-201117-11-2011none52malePancreasnoGEM13-12-201011-04-201111-04-2011none69malePancreasnoGEM12-08-201014-10-201002-11-2010none62femalePancreasnoGEM14-01-201018-02-201015-03-2010none66femalePancreasnoGEM14-12-200908-02-201001-06-2010none68malePancreasnoGEM06-10-200910-02-201030-11-2010none73malePancreasnoGEM14-07-200913-08-200921-11-2009none69malePancreasnoGEM07-07-200927-08-200917-10-2009none74femalePancreasnoGEM02-02-200923-03-200923-03-2009none64malePancreasnoGEM27-11-200821-01-200924-02-2009none57malePancreasnoGEM25-11-200808-06-200917-08-2009none63malePancreasnoGEM26-09-200807-11-200811-04-2009none75femalePancreasnoGEM29-05-200817-07-200810-06-2010none77malePancreasnoGEM21-05-200804-09-200802-06-2009none70malePancreasnoGEM11-01-200804-03-200814-04-2008none44malePancreasnoGEM10-10-200717-03-200823-05-2008none67malePancreasnoGEM27-07-200714-09-200710-11-2007none72malePancreasnoGEM02-04-200728-05-200706-08-2007none60malePancreasnoGEM27-12-200617-08-200720-02-2008none57femalePancreasnoGEM22-11-200610-01-200724-04-2007none72femalePancreasnoGEM30-03-200613-06-200604-02-2007none69malePancreasnoGEM10-08-201211-01-201313-04-2013none63femalePancreasnoGEM plus elrotinib16-09-201011-01-201229-02-2012none71malePancreasnoGnP20-02-201821-08-201831-08-2018none70malePancreasnoGnP28-11-201716-01-201827-03-2018none60malePancreasnoGnP02-10-201726-02-201812-03-2018none72femalePancreasnoGnP08-09-201716-03-201827-05-2018none61malePancreasnoGnP16-01-201821-02-201812-05-2018none68malePancreasnoGnP06-09-201709-01-201826-01-2018none69femalePancreasnoGnP21-03-201727-04-201722-01-2018none66malePancreasnoGnP22-11-201731-08-201831-08-2018none65femalePancreasnoGnP10-03-201701-05-201728-07-2017none65malePancreasnoGnP31-01-201720-07-201708-10-2017none75malePancreasnoGnP20-09-201631-01-201728-03-2017none75femalePancreasnoGnP26-09-201617-10-201615-11-2016none73femalePancreasnoGnP30-08-201620-12-201620-03-2017none81malePancreasnoGnP28-07-201613-10-201618-01-2017none62malePancreasnoGnP03-03-201706-04-201713-05-2017none67malePancreasnoGnP22-06-201621-09-201616-12-2016none77femalePancreasnoGnP12-05-201504-08-201503-09-2015none74maleSarcomayesGD14-10-201529-02-201629-08-2018cephem38femaleSarcomayesGD11-12-201417-06-201527-08-2015cephem51femaleSarcomayesGD13-08-201522-02-201615-03-2016cephem58femalePancreasyesGEM07-06-201704-09-201715-11-2017cephem75femaleBiliary tractyesGnP27-09-201722-02-201804-08-2018cephem78malePancreasyesGnP30-10-201719-01-201826-09-2018cephem50malePancreasyesGnP03-10-201621-06-201727-03-2018cephem63femalePancreasyesGnP23-07-201507-01-201630-06-2016cephem67femalePancreasyesGnP18-07-201719-03-201812-04-2018cephem59femalePancreasyesGnP29-06-201626-12-201622-01-2017cephem31maleSarcomayesGD19-12-201311-12-201422-06-2015new quinolone64maleSarcomayesGD16-04-201420-06-201425-11-2015new quinolone51maleSarcomayesGD10-11-201515-12-201504-10-2016new quinolone61femaleBiliary tractyesGEM24-11-201627-04-201713-01-2018new quinolone78femalePancreasyesGEM09-11-200926-04-201026-07-2010new quinolone66femalePancreasyesGEM plus erlotinib20-06-200804-11-200809-01-2009new quinolone45Fe maleBiliary tractYesGnP08-07-201510-06-201604-10-2016new Quinolone46FemalePancreasYesGnP22-03-201326-02-201531-08-2018New quinolone63MalePancreasYesGnP22-08-201324-10-201306-02-2014New quinolone63MalePancreasYesGnP30-01-201409-04-201421-08-2016New quinolone58MalePancreasYesGnP10-08-201514-10-201514-03-2016New quinolone69MalePancreasYesGnP07-06-201702-02-201831-08-2018New quinolone64FEMALEBiliary tractYesGC24-05-201608-02-201714-12-2017None62MaleBiliary tractYesGC25-08-201512-04-201601-01-2017None36MaleBiliary tractYesGCS21-07-200624-03-200821-05-2009None75MaleSarcomaYesGD24-08-201230-04-201303-02-2014None61FemaleSarcomaYesGD21-07-201731-08-201831-08-2018None38MaleSarcomaYesGD30-01-201506-03-201527-04-2015None44MaleSarcomaYesGD18-08-201627-10-201616-12-2016None80FemaleSarcomayesGD10-02-201408-04-201412-05-2014None56FemaleSarcomaYesGD21-02-201710-04-201709-05-2017None59MaleSarcomaYesGD04-06-200805-08-200805-09-2008None70MaleBiliary tractYesGEM26-03-200714-05-200706-08-2007None60MaleDKYesGEM04-02-201027-05-201009-09-2010None66MaleDKYesGEM26-02-201017-09-201011-02-2012None78FemaleDKYesGEM09-02-200628-03-200602-05-2006None60MalePancreasYesGEM12-11-201328-01-201404-06-2014None67FemalePancreasYesGEM08-11-201120-12-201120-12-2011None63MalePancreasYesGEM05-11-200914-10-201018-01-2011None57FemalePancreasYesGEM30-09-200919-11-200918-06-2010None62FemalePancreasYesGEM20-11-200626-01-200715-04-2007None41FemalePancreasYesGEM13-04-201217-08-201209-01-2013None74MalePancreasYesGnP12-02-201516-12-201512-01-2016None62MalePancreasYesGnP05-06-201514-09-201620-01-2017None54MalePancreasYesGnP10-04-201506-07-201522-01-2016None81MaleDKYesGEM16-01-201503-06-201631-08-2018β-lactamase inhibitor[^9]
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[^1]: **Note:** *P*-values were calculated using chi-squared test or Wilcoxon or Mann--Whitney test.

[^2]: **Abbreviations:** CUP, cancer of unknown primary; nabPTX, nanoparticle albumin binding paclitaxel; GEM, gemcitabine.

[^3]: **Notes:** *P*-value of response rate between two groups. Antibiotics-untreated group vs antibiotics-treated group *P*=0.0356. *P*-value of disease control rate between each group. Antibiotics-untreated group vs antibiotics-treated group *P*=0.0071.

[^4]: **Abbreviations:** CR, complete response; DCR, disease control rate; PD, progression disease; PR, partial response; RR, response rate; SD, stable didease.

[^5]: **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^6]: **Note:** *P*-values were analyzed using Pearson's chi-square test.

[^7]: **Abbreviation:** GEM, gemcitabine.

[^8]: **Notes:** Other cancer: CUP, NEC, duodenal cancer, breast cancer, urinary bladder cancer. *P*-value was calculated using log-rank test.

[^9]: **Abbreviations:** CUP, Cancer of unknown primary; NEC, Neuroendocrine carcinoma; GEM, Gemcitabine; GnP, GEM+nabPTX; GC, GEM plus cisplatin; GD, GEM plus docetaxel; GCS, GEM plus cisplatin plus S-1.
